Pacira Pharmaceuticals (82P) AI Stock Analysis

0 Followers

Pacira Pharmaceuticals

(Frankfurt:82P)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Deleveraged balance sheetSubstantial debt reduction has left Pacira with a conservative capital structure and greater financial flexibility. Lower leverage reduces financing pressure, supports continued investment in products and clinical programs, and improves resilience if procedure volumes or earnings fluctuate.

Negative Factors

Sharp TTM revenue declineThe steep TTM revenue contraction raises questions about the durability of Pacira's recovery and the consistency of demand across its portfolio. Although the latest quarter improved, the business must sustain growth over multiple periods to rebuild earnings scale and commercial momentum.

Pacira Pharmaceuticals (82P) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.46B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 38.3
Beta (1Y): 0.62
Revenue Growth: -1.49%
EPS Growth: 87.61%
Country: Germany
Employees: 827
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable lip...

Pacira Pharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:37.61%|Next Earnings Date:Mar 04, 2027

Earnings Call SentimentPositive

The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.

Positive Updates

Consolidated Revenue Growth

Second quarter total revenues of $192.4 million, up 6% year-over-year versus Q2 2025.

Negative Updates

Macroeconomic Headwinds Impacting Elective Procedures

Softness in elective soft tissue procedures, particularly in hospital inpatient settings where EXPAREL is not reimbursed outside the bundle, led to variable procedure demand and moderated near-term growth in some segments.

Company Guidance

Pacira updated 2026 guidance to total revenue of $735–760M (down from $745–770M reflecting the Zimmer/iovera divestiture) while reiterating EXPAREL net product sales of $600–620M; SG&A is now guided to $310–330M (vs. prior $320–340M), stock‑based compensation $54–59M (vs. $54–62M), non‑GAAP gross margin 77–79%, non‑GAAP R&D $105–115M, and depreciation of about $30M, with ~ $7M expected from a veterinary licensing agreement; Q2 datapoints cited were revenue $192.4M (+6% y/y), EXPAREL net sales $147.8M (+3%) with ~4% volume growth, Q2 non‑GAAP gross margin 78%, GAAP net income $4.7M ($0.12/sh), adjusted EBITDA ≈ $48.7M, and $251M cash/investments (plus a $70M upfront Zimmer payment); management noted near‑term margin benefit from selling lower‑cost EXPAREL inventory and expects Q4 margins to be slightly below the full‑year range due to higher‑cost inventory and shutdown-related costs.

Pacira Pharmaceuticals Risk Analysis

Pacira Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.We may not realize the anticipated benefits of the divestiture of iovera°.Q2, 2026

2.We may not receive some or all of the potential revenue-based milestone payments associated with the divestiture of iovera°.Q2, 2026

Pacira Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:82P against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	77Outperform	$1.24B	12.71	12.59%	―	3.11%	-4.26%
ANIP	72Outperform	$1.64B	13.72	20.00%	―	25.94%	203.25%
COLL	69Neutral	$760.42M	20.34	12.49%	―	7.68%	-34.31%
TEVA	65Neutral	$49.58B	101.81	9.18%	―	2.99%	-28.63%
AMRX	58Neutral	$7.45B	50.49	131.71%	―	8.88%	2272.07%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:82P and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:82P	Pacira	32.20	11.80	57.84%
TEVA	Teva Pharmaceutical Industries Limited	43.24	17.24	66.31%
ANIP	Ani Pharmaceuticals	71.09	-13.46	-15.92%
AMPH	Amphastar Pharmaceuticals Inc	28.60	2.23	8.46%
COLL	Collegium Pharmaceutical Inc.	24.81	-21.57	-46.51%
AMRX	Amneal Pharma	21.71	10.19	88.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pacira Pharmaceuticals AI Stock Analysis